Qiming backs Abbisko in $42M series B

Abbisko raised a $42 million series B round led by new investor Qiming Venture Partners to advance its oncology compounds into the clinic and further expand its discovery pipeline.

Abbisko Therapeutics Co. Ltd. (Shanghai, China) plans to start Phase I trials of ABSK011 and ABSK021, its most advanced compounds, in the coming months. ABSK011 and ABSK021 are small molecule inhibitors of FGFR4 for hepatocellular carcinoma (HCC) and CSF1R for solid tumors, respectively...